ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024
Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Protein Spatial Structure Meets Artificial Intelligence: Revolutionizing Drug Synergy-Antagonism in Precision Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Pooled it
- Regulatory B-cell states in NSCLC immunotherapy resistance: mechanisms, spatial context and translational implications.Cancer immunology, immunotherapy : CII · 2026Review
- Nanoadjuvant-integrated organic biomaterials for immune engineering: Mechanisms, design strategies, and translational applications.Materials today. Bio · 2026Review
- PRELID1 and VDAC3 Coordinate a Senescence-Like State in Germinal Center B Cells to Promote IL-7-Driven Antitumor Immunity in Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Reshaping the colorectal cancer immune microenvironment: insights from single-cell and spatial omics.Cancer cell international · 2026Review
- PIK-III-Mediated Elevation of Thiamine Re-Sensitises Renal Cell Carcinoma to Cuproptosis via Activating PDHA1.Cell proliferation · 2026Article
- Acupuncture in remodeling the tumor microenvironment: current status and challenges.Frontiers in immunology · 2026Review
- ESR1 Expression Negatively Correlates with Immune Cell Infiltration and Response to Immune Checkpoint Inhibitors in Estrogen Receptor-Positive/HER2-Negative Breast Cancer.Annals of surgical oncology · 2026Article
- Advances in protein ubiquitination modification and immune evasion of breast cancer.Frontiers in cell and developmental biology · 2026Review
- Article
- The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers.Biomarker research · 2025Review
- p53/PD-L1 co-expression predicts poor prognosis in diffuse large B-cell lymphoma.Discover oncology · 2025Article
- Integrative PANoptosis gene profiling reveals prognostic and therapeutic insights in prostate cancer.Biomolecules & biomedicine · 2025Article
- Lactylation-Related Gene LILRB4 Predicts the Prognosis and Immunotherapy of Prostate Cancer Based on Machine Learning.Journal of cellular and molecular medicine · 2025Article
- Tumor-infiltrating B cells in non-small cell lung cancer: current insights and future directions.Cancer cell international · 2025Review
- TMEM115: a promising marker for glioma immunotherapy and prognosis.Frontiers in immunology · 2025Article
- TSPAN4Frontiers in immunology · 2025Article
- The dual immunomodulatory role of B cells in tumorigenesis: mechanisms, microenvironment crosstalk, and therapeutic implications.Frontiers in immunology · 2025Review
- Multi-omics profiling unravel the immune landscape diversity by prognostic signatures of immunotherapy response in triple-negative breast cancer.Frontiers in immunology · 2025Article
- Distribution characteristics and prognostic value of TIM-1 in patients with lung adenocarcinoma.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
B cells are crucial component of humoral immunity, and their role in the tumor immune microenvironment (TME) has garnered significant attention in recent years. These cells hold great potential and application prospects in the field of tumor immunotherapy. Research has demonstrated that the TME can remodel various B cell functions, including proliferation, differentiation, antigen presentation, and antibody production, thereby invalidating the anti-tumor effects of B cells. Concurrently, numerous immune checkpoints (ICs) on the surface of B cells are upregulated. Aberrant B-cell IC signals not only impair the function of B cells themselves, but also modulate the tumor-killing effects of other immune cells, ultimately fostering an immunosuppressive TME and facilitating tumor immune escape. Blocking ICs on B cells is beneficial for reversing the immunosuppressive TME and restoring anti-tumor immune responses. In this paper, the intricate connection between B-cell ICs and the TME is delved into, emphasizing the critical role of targeting B-cell ICs in anti-tumor immunity, which may provide valuable insights for the future development of tumor immunotherapy based on B cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.